ScripBioMarin Pharmaceutical said on 16 May that it will acquire Inozyme Pharma for $4 per share, or $270m, in an all-cash transaction expected to close during the third quarter of this year – the first de
ScripSpruce Biosciences is securing rights to a shelved BioMarin rare disease candidate in a bid to revive its pipeline – but it will need additional funding to get that program to market. On 15 April, the
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,
ScripAtsena Therapeutics thinks it can be a success story in the gene therapy field, where some companies have recently stumbled, with the closure of a funding round that it plans to use especially for its